DK1284952T3 - Substituerede chalconer som terapeutiske kompositioner - Google Patents

Substituerede chalconer som terapeutiske kompositioner

Info

Publication number
DK1284952T3
DK1284952T3 DK01914064T DK01914064T DK1284952T3 DK 1284952 T3 DK1284952 T3 DK 1284952T3 DK 01914064 T DK01914064 T DK 01914064T DK 01914064 T DK01914064 T DK 01914064T DK 1284952 T3 DK1284952 T3 DK 1284952T3
Authority
DK
Denmark
Prior art keywords
group
4alkyl
compounds
therapeutic compositions
substituted
Prior art date
Application number
DK01914064T
Other languages
English (en)
Inventor
Gerard Andrew Potter
Paul Crispin Butler
Elugba Wanogho
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of DK1284952T3 publication Critical patent/DK1284952T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
    • C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01914064T 2000-03-27 2001-03-26 Substituerede chalconer som terapeutiske kompositioner DK1284952T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0007401.3A GB0007401D0 (en) 2000-03-27 2000-03-27 Substituted chalcones as therapeeutic compounds

Publications (1)

Publication Number Publication Date
DK1284952T3 true DK1284952T3 (da) 2006-10-30

Family

ID=9888505

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01914064T DK1284952T3 (da) 2000-03-27 2001-03-26 Substituerede chalconer som terapeutiske kompositioner

Country Status (14)

Country Link
US (1) US6787672B2 (da)
EP (1) EP1284952B1 (da)
JP (1) JP5235257B2 (da)
AT (1) ATE330928T1 (da)
AU (1) AU784609B2 (da)
CA (1) CA2403900C (da)
CY (1) CY1107519T1 (da)
DE (1) DE60120962T2 (da)
DK (1) DK1284952T3 (da)
ES (1) ES2269360T3 (da)
GB (1) GB0007401D0 (da)
NZ (1) NZ521595A (da)
PT (1) PT1284952E (da)
WO (1) WO2001072680A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123780D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
NZ552298A (en) * 2004-05-23 2011-04-29 Gerard M Housey Method for identifying inhibitors or activators of a theramutein by comparing the phenoresponse of cells exposed to a test compound
KR100597871B1 (ko) * 2004-06-08 2006-07-06 학교법인 영남학원 방향환을 함유하는 신규 프로페논 유도체 및 이를 함유하는 항염증제
DE102006018988B3 (de) * 2006-04-25 2007-08-09 Nateco2 Gmbh & Co. Kg Verfahren zur Herstellung eines Xanthohumol-haltigen Pulvers hoher Reinheit und dessen Verwendung
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
JP5302328B2 (ja) 2007-11-21 2013-10-02 オキシジーン, インコーポレイテッド 造血性新生物を治療するための方法
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2011009826A2 (en) 2009-07-21 2011-01-27 ADAMED Sp.z o.o. Novel chalcone derivatives with cytotoxic activity
CN102397269B (zh) * 2011-09-20 2015-01-07 温州医学院 查尔酮类化合物在制备抗炎药物中的应用
KR101333735B1 (ko) * 2011-11-01 2013-11-27 건국대학교 산학협력단 디페닐프로페논 화합물를 유효성분으로 포함하는 신경계 염증질환 예방 및 치료용 약학조성물
CN103102283B (zh) * 2011-11-09 2014-05-28 南京大学 一种查耳酮肟类化合物作为新型免疫抑制剂的制备方法与用途
CN103664689A (zh) * 2013-11-04 2014-03-26 南京大学 对癌细胞微管蛋白聚合有抑制作用的一类查尔酮肟衍生物及其制备方法
KR101558500B1 (ko) * 2014-02-26 2015-10-12 건국대학교 산학협력단 신규한 메톡시칼콘 유도체 및 그 항암제로의 용도
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のvdasの使用
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
CN115850048B (zh) * 2022-12-01 2024-05-10 东南大学 一种合成2芳基丁烯酮类化合物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279930A (en) 1978-10-10 1981-07-21 The Upjohn Company Process for treating inflammation
JPS60237039A (ja) * 1984-05-08 1985-11-25 Nippon Oil & Fats Co Ltd ベンザルアセトフエノン及びその誘導体の製造方法
JPS6176433A (ja) 1984-09-21 1986-04-18 Toyobo Co Ltd 新規なカルコン誘導体
LU86715A1 (fr) 1986-12-16 1988-07-14 Oreal Composition cosmetique contenant des derives hydroxyles de chalcone et son utilisation pour la protection de la peau et des cheveux contre les radiations lumineuses,nouveaux derives hydroxyles de chalcone utilises et leur procede de preparation
JPH02142717A (ja) 1988-11-22 1990-05-31 Kanebo Ltd 養毛化粧料
JPH05246932A (ja) 1992-03-04 1993-09-24 Nippon High Potsukusu:Kk 3,4−ジヒドロキシカルコン誘導体
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
JPH09501920A (ja) 1993-08-19 1997-02-25 ワーナー−ランバート・コンパニー 非ペプチドエンドセリンアンタゴニスト▲i▼
JPH08188546A (ja) 1995-01-04 1996-07-23 Kyowa Hakko Kogyo Co Ltd カルコン誘導体
GB9519490D0 (en) 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
EP0996432A2 (en) * 1997-06-26 2000-05-03 Statens Seruminstitut Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
DE69918950T2 (de) 1998-02-06 2005-07-28 De Montfort University Durch hydroxylierung aktivierte medikamentvorstufen
GB9802522D0 (en) 1998-02-06 1998-04-01 Montford University De Hydroxylation activated prodrugs
EP1242352A2 (en) 1999-12-23 2002-09-25 University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states

Also Published As

Publication number Publication date
US6787672B2 (en) 2004-09-07
DE60120962T2 (de) 2007-02-08
AU3945001A (en) 2001-10-08
AU784609B2 (en) 2006-05-11
ES2269360T3 (es) 2007-04-01
WO2001072680A1 (en) 2001-10-04
CA2403900C (en) 2011-02-08
GB0007401D0 (en) 2000-05-17
NZ521595A (en) 2005-04-29
US20030100538A1 (en) 2003-05-29
CY1107519T1 (el) 2013-03-13
JP5235257B2 (ja) 2013-07-10
JP2003528842A (ja) 2003-09-30
EP1284952B1 (en) 2006-06-21
DE60120962D1 (de) 2006-08-03
PT1284952E (pt) 2006-11-30
CA2403900A1 (en) 2001-10-04
EP1284952A1 (en) 2003-02-26
ATE330928T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
DE60120962D1 (de) Substituierte chalkone als arzneimitteln
AP1422A (en) 6.Alpha.,9.alpha.-difluoro-17.alpha.-&#39;(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent.
LU91761I2 (fr) Vernakalant et ses dérivés pharmaceutiquement acceptables et en particulier son sel d&#39;hydrochlorure (BRINAVESS®)
ATE440603T1 (de) 8-hydroxychinolinderivate
WO2001064642A3 (en) Benzamides and related inhibitors of factor xa
DK1392714T3 (da) Steroider som agonister for FXR
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2001056989A3 (en) Inhibitors of factor xa
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
AUPR213700A0 (en) Antiviral agents
AR036100A1 (es) Derivados de naftil benzofurano sustituidos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos que son inhibidores del inhibidor-1 activador de plasminogeno (pai-1)
MY143391A (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
SE0101932D0 (sv) Pharmaceutical combinations
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
BR0005616A (pt) 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-i l-4-o-tolil-piridin-3-il)-isobutiramida
WO2001057021A3 (en) 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
ATE308540T1 (de) Antithrombosemittel
UY25824A1 (es) Antagonista del receptor de vitronectina
WO2003028713A3 (en) 3,4-methylenedioxy-substituted chalcones as therapeutic agents
GB0103046D0 (en) Organic Compounds
SE0004827D0 (sv) Therapeutic compounds
ES2284970T3 (es) Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer.